{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:04:48Z","timestamp":1791288288361,"version":"4.3.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,3,1]]},"abstract":"<jats:p>Liver toxicity caused by high-dose myeloablative therapy leads to significant morbidity after hematopoietic cell transplantation. We examined the hypothesis that liver toxicity after cyclophosphamide and total body irradiation is related to cyclophosphamide through its metabolism to toxins. Cyclophosphamide was infused at 60 mg\/kg over 1 to 2 hours on each of 2 consecutive days, followed by total body irradiation. Plasma was analyzed for cyclophosphamide and its major metabolites. Liver toxicity was scored by the development of sinusoidal obstruction syndrome (veno-occlusive disease) and by total serum bilirubin levels. The hazards of liver toxicity, nonrelapse mortality, tumor relapse, and survival were calculated using regression analysis that included exposure to cyclophosphamide metabolites (as the area under the curve). Of 147 patients, 23 (16%) developed moderate or severe sinusoidal obstruction syndrome. The median peak serum bilirubin level through day 20 was 2.6 mg\/dL (range, 0.5-41.1 mg\/dL). Metabolism of cyclophosphamide was highly variable, particularly for the metaboliteo-carboxyethyl-phosphoramide mustard, whose area under the curve varied 16-fold. Exposure to this metabolite was statistically significantly related to sinusoidal obstruction syndrome, bilirubin elevation, nonrelapse mortality, and survival, after adjusting for age and irradiation dose. Patients in the highest quartile ofo-carboxyethyl-phosphoramide mustard exposure had a 5.9-fold higher risk for nonrelapse mortality than did patients in the lowest quartile. Engraftment and tumor relapse were not statistically significantly related to cyclophosphamide metabolite exposure. Increased exposure to toxic metabolites of cyclophosphamide leads to increased liver toxicity and nonrelapse mortality and lower overall survival after hematopoietic cell transplantation.<\/jats:p>","DOI":"10.1182\/blood-2002-06-1860","type":"journal-article","created":{"date-parts":[[2003,2,12]],"date-time":"2003-02-12T19:59:36Z","timestamp":1045079976000},"page":"2043-2048","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":312,"title":["Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation"],"prefix":"10.1182","volume":"101","author":[{"given":"George B.","family":"McDonald","sequence":"first","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, and the Departments of Medicine and Pharmaceutics, University of Washington Schools of Medicine and Pharmacy, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Slattery","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, and the Departments of Medicine and Pharmaceutics, University of Washington Schools of Medicine and Pharmacy, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle E.","family":"Bouvier","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, and the Departments of Medicine and Pharmaceutics, University of Washington Schools of Medicine and Pharmacy, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Ren","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, and the Departments of Medicine and Pharmaceutics, University of Washington Schools of Medicine and Pharmacy, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami L.","family":"Batchelder","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, and the Departments of Medicine and Pharmaceutics, University of Washington Schools of Medicine and Pharmacy, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Kalhorn","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, and the Departments of Medicine and Pharmaceutics, University of Washington Schools of Medicine and Pharmacy, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Gary","family":"Schoch","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, and the Departments of Medicine and Pharmaceutics, University of Washington Schools of Medicine and Pharmacy, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Anasetti","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, and the Departments of Medicine and Pharmaceutics, University of Washington Schools of Medicine and Pharmacy, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted","family":"Gooley","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, and the Departments of Medicine and Pharmaceutics, University of Washington Schools of Medicine and Pharmacy, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111822144454300_B1","volume-title":"Hematopoietic cell transplantation.","author":"Thomas","year":"1999","edition":"2nd ed."},{"key":"2019111822144454300_B2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","article-title":"Venocclusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients.","volume":"118","author":"McDonald","year":"1993","journal-title":"Ann Intern Med."},{"key":"2019111822144454300_B3","first-page":"3599","article-title":"Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation.","volume":"92","author":"Carreras","year":"1998","journal-title":"Blood."},{"key":"2019111822144454300_B4","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/0003-4819-125-8-199610150-00001","article-title":"Withdrawing life support from mechanically ventilated recipients of bone marrow transplants: a case for evidence-based guidelines.","volume":"125","author":"Rubenfeld","year":"1996","journal-title":"Ann Intern Med."},{"key":"2019111822144454300_B5","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/hep.510240414","article-title":"Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation.","volume":"24","author":"DeLeve","year":"1996","journal-title":"Hepatology."},{"key":"2019111822144454300_B6","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/hep.1840190515","article-title":"Venocclusive disease of the liver after marrow transplantation: histologic correlates of clinical signs and symptoms.","volume":"19","author":"Shulman","year":"1994","journal-title":"Hepatology."},{"key":"2019111822144454300_B7","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","article-title":"Veno-occlusive disease of the liver following bone marrow transplantation.","volume":"44","author":"Jones","year":"1987","journal-title":"Transplantation."},{"key":"2019111822144454300_B8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-2002-23204","article-title":"Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (venocclusive disease).","volume":"22","author":"Deleve","year":"2002","journal-title":"Semin Liver Dis."},{"key":"2019111822144454300_B9","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1200\/JCO.1992.10.6.995","article-title":"Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response.","volume":"10","author":"Ayash","year":"1992","journal-title":"J Clin Oncol."},{"key":"2019111822144454300_B10","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.1991.9.7.1215","article-title":"Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new drug dosing regimens.","volume":"9","author":"Braverman","year":"1991","journal-title":"J Clin Oncol."},{"key":"2019111822144454300_B11","first-page":"810","article-title":"Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.","volume":"55","author":"Chen","year":"1995","journal-title":"Cancer Res."},{"key":"2019111822144454300_B12","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1056\/NEJM199804023381405","article-title":"Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia.","volume":"338","author":"Hansen","year":"1998","journal-title":"N Engl J Med."},{"key":"2019111822144454300_B13","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/00007890-199211000-00015","article-title":"Treatment of graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody.","volume":"54","author":"Anasetti","year":"1992","journal-title":"Transplantation."},{"key":"2019111822144454300_B14","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0009-9236(98)90178-3","article-title":"Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients.","volume":"64","author":"Ren","year":"1998","journal-title":"Clin Pharmacol Ther."},{"key":"2019111822144454300_B15","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0378-4347(99)00300-X","article-title":"Analysis of cyclophosphamide and five metabolites from human plasma using liquid chromatography-mass spectrometry and gas chromatography-nitrogen-phosphorus detection.","volume":"732","author":"Kalhorn","year":"1999","journal-title":"J Chromatogr B Biomed Sci Appl."},{"key":"2019111822144454300_B16","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/00007890-198506000-00005","article-title":"The clinical course of 53 patients with veno-occlusive disease of the liver after marrow transplantation.","volume":"36","author":"McDonald","year":"1985","journal-title":"Transplantation."},{"key":"2019111822144454300_B17","first-page":"1636","article-title":"Hepatobiliary complications of hematopoietic cell transplantation.","volume-title":"Schiff's Diseases of the Liver.","author":"Strasser","year":"2003","edition":"9th ed."},{"key":"2019111822144454300_B18","first-page":"915","article-title":"A biologically active metabolite of cyclophosphamide.","volume":"33","author":"Colvin","year":"1973","journal-title":"Cancer Res."},{"key":"2019111822144454300_B19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0006-2952(74)90318-9","article-title":"Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide.","volume":"23","author":"Connors","year":"1974","journal-title":"Biochem Pharmacol."},{"key":"2019111822144454300_B20","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/bms.1200020109","article-title":"Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite.","volume":"2","author":"Struck","year":"1975","journal-title":"Biomed Mass Spectrom."},{"key":"2019111822144454300_B21","first-page":"4229","article-title":"Oxidation of cyclophosphamide to 4-hydroxycyclophosphomide and deschloroethylcyclophosphamide in human liver microsomes.","volume":"57","author":"Ren","year":"1997","journal-title":"Cancer Res."},{"key":"2019111822144454300_B22","first-page":"519","article-title":"Urinary metabolites of the antitumor agent cyclophosphamide.","volume":"7","author":"Struck","year":"1971","journal-title":"Mol Pharmacol."},{"key":"2019111822144454300_B23","first-page":"1150","article-title":"Bioassay and relative cytotoxic potency of cyclophosphamide metabolites generated in vitro and in vivo.","volume":"33","author":"Sladek","year":"1973","journal-title":"Cancer Res."},{"key":"2019111822144454300_B24","first-page":"5156","article-title":"Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia.","volume":"44","author":"Hilton","year":"1984","journal-title":"Cancer Res."},{"key":"2019111822144454300_B25","first-page":"1549","article-title":"Restoration of sensitivity to oxazaphosphorines by inhibitors of aldehyde dehydrogenase activity in cultured oxazaphosphorine-resistant L1210 and cross-linking agent-resistant P388 cell lines.","volume":"45","author":"Sladek","year":"1985","journal-title":"Cancer Res."},{"key":"2019111822144454300_B26","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1016\/0006-2952(87)90269-3","article-title":"Effects of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of murine late spleen colony-forming cells (day-12 CFU-S) and hematopoietic repopulating cells to mafosfamide (ASTA Z 7557).","volume":"36","author":"Kohn","year":"1987","journal-title":"Biochem Pharmacol."},{"key":"2019111822144454300_B27","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0005-2736(99)00169-8","article-title":"Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP-2 mediated drug resistance.","volume":"1461","author":"Konig","year":"1999","journal-title":"Biochim Biophys Acta."},{"key":"2019111822144454300_B28","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/hep.510290615","article-title":"Characterization of a reproducible rat model of hepatic veno-occlusive disease.","volume":"29","author":"DeLeve","year":"1999","journal-title":"Hepatology."},{"key":"2019111822144454300_B29","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/hep.510310224","article-title":"Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat.","volume":"31","author":"Wang","year":"2000","journal-title":"Hepatology."},{"key":"2019111822144454300_B30","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1445-5994.1993.tb01447.x","article-title":"Cyclophosphamide related hepatotoxicity.","volume":"23","author":"Clelland","year":"1993","journal-title":"Aust N Z J Med."},{"key":"2019111822144454300_B31","first-page":"967","article-title":"Veno-occlusive disease of the liver induced by low dose cyclophosphamide.","volume":"7","author":"Modzelewski","year":"1994","journal-title":"Mod Pathol."},{"key":"2019111822144454300_B32","first-page":"149","article-title":"Hepatotoxicity of cyclophosphamide in man: pharmacokinetic analysis.","volume":"61","author":"Honjo","year":"1988","journal-title":"Res Commun Chem Pathol Pharmacol."},{"key":"2019111822144454300_B33","first-page":"584","article-title":"Pathogenesis of veno-occlusive liver disease after radiation.","volume":"104","author":"Fajardo","year":"1980","journal-title":"Arch Pathol Lab Med."},{"key":"2019111822144454300_B34","doi-asserted-by":"crossref","first-page":"322","DOI":"10.2307\/3578033","article-title":"Radiation hepatopathy of the rat: microvascular fibrosis and enhancement of liver dysfunction by diet and drugs.","volume":"129","author":"Geraci","year":"1992","journal-title":"Radiat Res."},{"key":"2019111822144454300_B35","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1259\/0007-1285-55-659-847","article-title":"Repair of radiation damage in noncycling parenchymal hepatocytes.","volume":"55","author":"Jirtle","year":"1982","journal-title":"Br J Radiol."},{"key":"2019111822144454300_B36","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/1097-0142(19881001)62:7<1275::AID-CNCR2820620705>3.0.CO;2-I","article-title":"Glutathione monoethyl ester can selectively protect liver from high dose BCNU or cyclophosphamide.","volume":"62","author":"Teicher","year":"1988","journal-title":"Cancer."},{"key":"2019111822144454300_B37","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1055\/s-2007-1007173","article-title":"Glutathione defense in non-parenchymal cells.","volume":"18","author":"DeLeve","year":"1998","journal-title":"Semin Liver Dis."},{"key":"2019111822144454300_B38","first-page":"114","article-title":"Induction of hepatic veno-occlusive disease in dogs.","volume":"126","author":"Shulman","year":"1987","journal-title":"Am J Pathol."},{"key":"2019111822144454300_B39","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1182\/blood.V89.8.3055","article-title":"Marrow transplantation for chronic myeloid leukemia\u2014the influence of plasma busulfan levels on the outcome of transplantation.","volume":"89","author":"Slattery","year":"1997","journal-title":"Blood."},{"key":"2019111822144454300_B40","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1182\/blood.V80.9.2425.2425","article-title":"Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation.","volume":"80","author":"Yeager","year":"1992","journal-title":"Blood."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/5\/2043\/1263602\/h80503002043.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/5\/2043\/1263602\/h80503002043.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T03:15:02Z","timestamp":1574133302000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/101\/5\/2043\/106684\/Cyclophosphamide-metabolism-liver-toxicity-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3,1]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2003,3,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-06-1860","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2003,3,1]]}}}